Andrew McGrath, Haiyan Huang, Jean-Francois Brazeau, Zirong Zhang, Christopher O. Audu,

Metrics&More ArticleRecommendations sı SupportingInformation

PROTACsareheterobifunctionalmoleculesthatconsistofatarget-bindingmoietyandanE3ligasebindingmoiety,connectedbya
linker.Thesefragmentsarefrequentlyunitedviaamidebonds.Whilestraightforwardtosynthesize,amides mayimpartsuboptimal
drug properties to the overall molecule. From a systems level perspective, we envisioned that the potency of PROTACs could be
modulatedthroughselectionofreactionconditions�whereindifferentcatalystsproducedistinctlinkersfromthesametwobuilding
blocks.WepresentasuiteofBRD4PROTACdegraderspreparedviafournewamine−acidcouplingreactionsalongsidetheclassic
amide coupling. Our findings reveal that variations in reaction conditions affect the physicochemical properties of PROTACs,
resultinginaspectrumofproperties.Notably,severalnewPROTACsdemonstratedenhancedBRD4degradationefficacycompared
to those employing amide linkers, emphasizing the potential of systems chemistry as a therapeutic optimization strategy.
■

Control over physicochemical properties using chemical reaction conditions. Here, we experimentally validate control
synthesis is typically achieved by varying starting materials to ofcompoundbioactivityinanintermolecularsettingthrougha
introduce molecular diversity. Molecular functions such as systemslevelintegrationofinterconnectedparameters(Figure
selective tissue distribution or metabolic stability of pharma- 1a).Weenvisionthatsuchsystemschemistryexplorationswill
ceuticalsarelinkedtophysicochemicalpropertiesandchemical become increasingly important since computational predic-
structure. While the connection of structure and function is tions of bioactivity are becoming more precise while synthesis
well established, the use of reaction conditions to drive and bioassay experiments becoming more automated.1
function, through a systems-level chemistry evaluation,1 is The emergence of proteolysis targeting chimeras (PRO-
underexplored. An interconnected and interdependent net- TACs) as a powerful therapeutic modality exemplifies the
work of building blocks, reaction conditions, transformations, significant impact of linker composition, not only on activity,
structures,properties,andfunctioncanbeviewedonasystems
but also on the bulk physicochemical properties of these
levelwhere,forinstance,thechoiceofareactioncatalystcould protein degraders.5−10 PROTACs are heterobifunctional
driveacellularphenotypicoutcome(Figure1a).Forinstance,

Revised: November6, 2024
mides underwent diverse intramolecular rhodium-catalyzed

Journal of Medicinal Chemistry pubs.acs.org/jmc Article

Figure 1. (a) Systems chemistry: building blocks, conditions, transformations, structure, properties, and function are interconnected and
interdependent.(b)80transformations(ref2)areappliedto1andacollectionofcommerciallyavailableamine-containingpartialPROTACs(see

SupportingInformation)togiveachemicalspace,displayedasat-distributedstochasticneighborembedding(tSNE),withamide,ester,amine,
alkane,ketoneproductshighlightedincolor.(c)Diverseamine−acidcouplingson1and2canproduceamide(3),ester(4),alkane(5),ketone
(6),or amine (7),congeners.
molecules that contain a ligand to recruit an E3 ubiquitin properties of the molecules produced, including molecular
ligase, a ligand to bind the protein of interest (POI), and a weight,LogP,formalcharge,andpolarsurfacearea(PSA)(see
linker conjoining the two ligands, leading to event driven Supporting Information) were calculated and compared using
pharmacology that is catalytic and agnostic of receptor a t-distributedstochastic neighbor embedding (tSNE) (Figure
occupancy.11 As such, PROTACs have a unique ability to 1b). This analysis revealed the transformations forming amide
target “undruggable” proteins. The explosion of interest in (purple dots) and amine products (yellow dots) in general

PROTACs has led to an extensive, commercially available occupy their own chemical space, suggesting these trans-
toolkitoflinkerandE3ligasebindingbuildingblocks,mostof formations impart a larger effect on the overall properties of
which terminate in an amine or carboxylic acid. Indeed, the themolecule.Comparatively,theester(pinkdots),alkane(red
coupling amines and acids to form amides is one of the most dots), and ketone products (orange dots) overlap, indicating
popular methods in the synthesis of PROTACs.12,13 Other these transformations exert a more nuanced effect on the
tactics include esterification,14 click chemistry,15 S Ar,16 property space occupied by the products. This is further

Buchwald−Hartwig coupling,17 and various other meth- exemplifiedbytheincorporationofbasicaminesintothelinker
ods.18−20 In a conventional amide coupling, when a primary portion of the starting amine (c.f. orange dots in the space
amine and carboxylic acid are united,21 the resultant amide mostlyoccupiedbyyellowdots).Notablepocketsofthisspace
motifbears onehydrogenbond donor(HBD) alongwith two remain inaccessible (gray dots), for instance from trans-
hydrogen bond acceptors (HBA) and is neutral in charge. In formations that retain the carboxylic acid or incorporate bond
thismanner,thetransformationitselfcanbeviewedasleaving rearrangements (see Supporting Information), representing
a physicochemical footprint on the product. However, if the synthetic methods that merit future investigation. However,
conditions used in the reaction are modified and an ester is the five transformations demonstrated here indeed cover a
produced instead, the product has one less HBD. It follows breadth of space and structure activity relationships when
that the properties, and thus the functional outcome, of a starting from the same two building blocks.
moleculeisdependentnotonlyuponthebuildingblocksused Herein, we developed a suite of amine−acid PROTACs
tocreateitbutalsothetransformationusedtounitethem.The linking reactions that produced either an amide, ester, amine,
diversecompositionandarrangementofatomsaccessedinthis alkane,orketonelinkage usingthewell-studiedbromodomain
way allows for a fine-tuning of properties from two building inhibitorJQ11andcereblon(CRBN)bindingpomalidomide-
blocksjustbychangingreactionconditions.4Whenweapplied derivedamine2toyieldtheclassicPROTACdBET1(3)and
80 possible transformations3 on acid 1 and a suite of derivatives 4−7 of (Figure 1c).22 Each of these methods
commercially available cereblon (CRBN) recruiting amines provides a unique way to pair a POI and a partial PROTAC,
in silico, a diverse property space emerged (Figure 1b). The andtheresultantcompounds spanarangeofphysicochemical

Journal of Medicinal Chemistry pubs.acs.org/jmc Article

Figure2.(a)Developingdiversereactionconditionstoproduceester,amine,alkane,andketone-linkedanalogsofamidedBET1(3)usinghigh-
throughputexperimentation.AssayyieldsweredeterminedbyUPLC-MS.(b)Esterarrayconditions:10μmolof1(1.0equiv),10(1.0equiv),base
(1.0equiv)andadditive(equivlisted)perwell.(c)Alkanearrayconditions:5μmol(2.0equiv)of8,10(1.0equiv),nickelcatalyst(40mol%),
ligand(40mol%),imideadditive(2.0equiv),Brønstedacid(2.0equiv),andmanganese(4.0equiv)perwell.(d)Ketonearrayconditions:5μmol
(2.0equiv) of 9,1.0 equivof 10,nickel catalyst(40mol %),ligand (40mol%), additive (2.0 equiv), andmanganese (4.0 equiv) per well.(e)

Aminearrayconditions:15μmolof1(1.5equiv),2(1.0equiv),catalysts(5mol%),ligand(10mol%),andphenylsilane(4equiv)perwell.All
wells contain 100 μL of solvent. PyBCamCN = (2Z,6Z)-N′2,N′6-Dicyanopyridine-2,6-bis(carboximidamide), MeOPyCamCN = 4-methoxy-N-
cyanopicolinimidamide PyCamCN = N-cyanopicolinimidamide, ttbtpy = 4,4′,4″-tritert-Butyl-2,2′:6′,2″-terpyridine, dtbpy = 4,4-ditert-
butylbipyridine,2CNPyr =2-cyanopyridine,Karstedt’s cat= Platinum(0)-1,3-divinyl-1,1,3,3-tetramethyldisiloxanecomplex.

Journal of Medicinal Chemistry pubs.acs.org/jmc Article
and pharmacological properties. Our suite of heterobifunc-
tional degraders, accessed from these CRBN amines and
carboxylic acid coupling transformations was also applied to a
vonHippel−Lindau(VHL)targetingamine.Theresultsofthis
systems-levelstudyhighlighttheintricateconnectivitybetween
reaction conditions, transformations, and biological function.
■

Potassium bromide (KBr) and bromomethyldiethyl malonate optimal conditions to deliver 6 in 36% assay yield (28%
facilitated the reaction as additives, but in lower yield than KI isolatedyield).Wewereintriguedbytherapiddecarbonylation
or sodium iodide (NaI). The best performing conditions used of the acyl fluoride 8 to give alkane product 5 as opposed to

KI and potassium tert-butoxide and gave 4 in 53% assay yield ketone product 6 when subjected to nickel and dtbpy, in
and 54% isolated yield. This protocol complements recently contrast to literature reports (Figure 3).7,36 Mechanistic
reported methods to access ester-linked PROTACs via total investigations in our lab and others37,41−43 have highlighted
synthesis.14 that subtle effects govern the decarbonylation event in nickel-

To access alkane and ketone linked products, we explored catalyzed reductive cross-couplings. In addition, ligands may
nickel-catalyzed reductive cross-coupling conditions. Related also play a role in governing the kinetics of decarbonylation;
methods employing nickel as the metal catalyst have emerged when the acyl carbonate of 1 and pyridinium salt of 2 were
as a powerful tool to link pyridinium salts31−35 and activated subjected to NiBr ·DME and dtbpy, only the decarbonylated
2
carboxylic acids,36−39 and we hypothesized that a related alkylcouplingproduct5wasobserved,albeitinloweryield.To
nickel-catalyzed system would best facilitate the formation of further probe this effect, we investigated other amine and
alkane(5)andketone(6)targets.Webeganourinvestigation carboxylicacidcouplingpartnersunderourreactionconditions
through coupling acyl fluoride 8 (Figure 3), generated in situ (see Supporting Information). In general, we have discovered
from1usingtetramethylfluoroformamidiniumhexafluorophos- that selectivity for C−C coupling is consistent in the case of
phate(TFFH)andprotonsponge,and10(thepyridiniumsalt primary pyridinium salts whereas only the ketone product is
of 2). Subjecting these coupling partners to nickel(II) observed when using secondary pyridinium salts. The rapid
bromide·glyme (NiBr ·DME), 4,4-di-tert-butylbipyridine decarbonylationisalsoobservedincarboxylicacidscontaining
2
(dtbpy), and elemental manganese produced alkane product aβ-diphenyliminegroup.Furtherinvestigationsintothiseffect
5. A thorough investigation of the interplay of imide additives are ongoing in our lab.
(see Supporting Information),40 nickel sources, ligands, and We next turned our attention to the formal reductive

Brønstedacid additives (Figure2c) wasconducted. Wefound amination between 1and 2to arriveat amine-linked products

Journal of Medicinal Chemistry pubs.acs.org/jmc Article

Figure4.Reductiveaminationconditionsappliedtoalibraryof(a)6aminesand(b)4acids.Allreactionsconductedusing10μmolofamine(1.0
equiv)and15μmolofacid(1.5equiv),PtCl (5mol%),BrettPhos(10mol%)andPhSiH (5.0equiv)at0.1M.(c)Resultsofthescreen(d)
2 3

Isolatedyieldsupon scaleupof select compoundson0.100 mmolscale relativeto the amine startingmaterial.
directly from an amine and acid. Based upon literature assolvent.OurobservationsconfirmedthatDMSOisessential
precedent,44,45 we believed the desired reactivity could be to achieving reactivity with these complex substrates, which
achieved using either platinum catalysts or contrasts reports on simpler substrates.44−46 Additionally,
tris(pentafluorophenyl)borane (BCF). BCF in dibutylether platinumcatalysisoutperformedboroncatalystswithplatinum-
(Bu O) produced a trace amount of desired amine 7 along (II) chloride being an optimal catalyst and BrettPhos as a
2
withamide3andrecoveredstartingmaterial,andnoreduction preferred ligand.
of the amide bond or the four other carbonyls. Further Exploration of Substrate Scope and Reaction Scale-
investigation of solvent effect demonstrated that DMSO Ups. To further explore the scope of the reductive amination
outperforms other polar aprotic solvents (see Supporting reactionwe applied our optimized condition toan array ofsix

Information)suggestingthatperformanceisnotentirelydriven amines including four partial PROTACs (2, 11−13), two
by solubility. Based upon these data we planned a screen linker type molecules (14, 15) (Figure 4a) and four
investigating solvents, catalysts, and ligands. Three catalysts pharmaceutically relevant carboxylic acids (1, 16−18) (Figure
(twobasedonplatinumalongwithBCF),andfourphosphine 4b).SincewehaveseenthatCRBNtargetingligandssuchas2
ligands, were surveyed by HTE using DMSO or dibutyl ether and 11 generally perform better in pure DMSO, and other

Journal of Medicinal Chemistry pubs.acs.org/jmc Article

Figure5.(a)Fivetransformationsappliedto1and2(CRBN),aswellas1and13(VHL).Allreactionsconductedat0.100mmolscalerelativeto
theamine.Amideconditions:1and2(1.0equiv),PyAOP(1.0equiv),andN-methylimidazole(1.0equiv)in1.0mLofsolvent(0.1M).Ester
reactionconditions:1and10(1.0equiv),KI(2.0equiv),andKOtBu(1.0equiv)in1.0mLsolvent(0.1M).CCandKetoneconditions:1(2.0
equiv),2(1.0equiv),nickelcatalyst(40mol%),ligand(40mol%),additive(2.0equiv),andmanganese(4.0equiv)in2.0mLsolvent0.05M.

Amineconditions:1(1.5equiv)and2(1.0equiv),PtCl (5mol%),BrettPhos(10mol%),andPhSiH (5.0equiv).(b)Chemoinformaticanalysis
2 3
of3−7. (c) Methodsusedto activate the amine oracidcoupling partner.(d) Chemoinformaticanalysis of 19,23−26.
systemsperformbetterusingamixtureofDMSOanddioxane, With optimized conditions for each transformation, we
wesettledon30%DMSOindioxane.Theseconditionsappear turned our attention toward the isolation of each compound
broadly applicable to late-stage derivatization as we saw on synthetically useful scale (0.1 mmol) (Figure 5a) using
productformedineverywell(Figure4c).Thisisremarkableas VHL targeting amine 13.7,8,48
the reactions are performed in the presence of functionalities We observed similar reactivity trends despite the incorpo-
rationofpotentiallysensitivefunctionalgroups.Isolatedyields
such as alcohols (12,13), acetonides (17), a dihydrouracil
onpreparativescalefoundtocorrelatewellwithassayyieldfor
(11), and an indole (16). Additionally, the reaction works on
each transformation and delivered both the CRBN and VHL
aliphatic as well as benzylic acids. To validate our screening
basedPROTACsinacceptablequantity.Ouramideconditions
protocol we isolated products from four wells on a 0.1 mmol
(seeSupportingInformation)yieldedcompound3in73%and
scale (19−22) (Figure 4d). In each of these reactions, we did
compound 23 in 47% yield, respectively. Applying our
not observe reduction of other carbonyls present in the
esterification conditions to each substrate yielded ester 4 in
molecule. These results as well as control experiments where
54% and ester 24 in 36% yield. Further, a one-pot protocol
theaminewasomitted(seeSupportingInformation)suggesta
(seeSupportingInformation)wasdevelopedtogive4directly
pathway where an aldehyde intermediate is formed prior to
from 1 to 2 in 28% yield. A slightly modified protocol using
coupling as opposed to amide formation and subsequent twoequivalentsofbasewasappliedtothehydrochloridesaltof
reduction.44,45,47Theester,alkane,andketonetransformations
13 to give 24 in 25% yield. Applying our alkane-forming
as well as the amide coupling were also applied to the same conditionsyielded5in33%and25in20%yield,respectively.
library of amine-acid coupling partners (see Supporting Applicationofourketone-formingconditionsyielded6and26

Information). in 28% and 19% yield, respectively. Finally, our conditions for

Journal of Medicinal Chemistry pubs.acs.org/jmc Article

E3ligase linkertype(#) MW CHILogD BRD4HTRFdegradationDC (nM) BRD4HTRFdegradationD (%)
7.4 50 max

Figure 6.BRD4HTRFdegradationassay: (a) CRBNseriesdegradationcurves (3−7).(b)VHL seriesdegradationcurves (19,23−26).

CRBNcellularnanoBRET assay.
reductive amination afforded 7 in 23% yield. It was found determined to be 2.16, with ester 4, alkane 5, and ketone 6
necessary to use 10% DMSO in dioxane as solvent to achieve giving values of 2.68, 2.81, and 2.57 respectively (Table 1).
optimal reactivity for the synthesis of 19. This adjustment Meanwhile, protonatable amine 7 had a significantly lower
furnished 19 in 23% yield. It is noteworthy that we did not logD at 1.66. The same trend follows for the VHL series
7.4
observe opening of the glutarimide ring under any of our with amide 23 having logD of 2.78 compared to 3.25, 3.38,
7.4
reaction conditions.49,50 3.16, and 2.30 for24,25,26, and19. Theability tomodulate

PropertiesofIsolated PROTACs.Withninenew dBET1 logD coupled with the option to vary molecular weight by
7.4
analogs in hand, cheminformatic calculations were performed up to 44 g/mol highlights the impact that reaction conditions
on each molecule to demonstrate that we can effectively can have on function when optimizing degraders.51
modulate theproperties of each final PROTAC by changes to In Vitro Activity of BRD4 PROTACs. Having established
thelinkercomposition(Figure5b,d).Whilebulkpropertiesare conditions to scale up and isolate the 10 BRD4 PROTACs
influenced by choice of building blocks (2 versus 13), each (3−7, 19, 23−26), in vitro profiling to assess BRD4
transformation also imparts its own effect on the overall degradation was initiated. We tested both CRBN-based (3−
propertiesofthemolecule,whichisakeytenetofoursystems 7) as well as VHL-based (19, 23−26) PROTACs in HEK293
chemistryvision.Notably,removalofoneHBD(amide/amine cellstoreadoutendogenousBRD4degradationDC andD
50 max
versus ester/alkane/ketone) can shift the calculated logP by values,52 using a BRD4 homogeneous time-resolved fluo-
over one log unit relative to the amide (3) as well as having a rescence(HTRF)degradationassay(Figure6).Inaddition,to
significantimpactonpolarsurfacearea(PSA)(seeSupporting distinguish on target BRD4 degradation from general cell

Information). This was validated experimentally through toxicity, CellTiter-Glo (CTG) was also conducted (see
determination of chromatographic hydrophobicity index Supporting Information). Within the CRBN-BRD4 PROTAC
(CHI) logD . For amide 3, the experimental value was series, we observed several molecules with more efficient
7.4

Journal of Medicinal Chemistry pubs.acs.org/jmc Article

Figure7.MoleculardynamicsimulationsofPROTACs3,4,and7boundtotheBRD4-BD1crystalstructure(PDB:6BOY).55Time-lapsesnap-
shotsfrom250nssimulationsareshownoverlaidanddepictedusingcolorchangesfromredtoblueindicatinginitialtofinalbindingpose.The
regionhighlightedwithagraycircleforthecomplexwith7demonstratesthattheaminecongenersamplesmanydifferentconformationsoverthe
250nssimulation,whichisobservablealsointheRMSFplotbelow,suggestingthatthecomplexwith7islessstableandhencesupportingthe
observationof loweraffinity. RMSF =root-mean-square fluctuation.

BRD4 degradation than amide dBET1 (3) (Figure 6a, Table 16.0nM,andCRBNbindingof528.5nM(livecells)and86.3
1).Theester4,alkane5andketone6weremorepotentthan nM (permeabilized cells). Of the newly synthesized analogs,
amide 3, with DC values of 5.4, 10.8, 9.2, and 95.0 nM, ester 4, alkane 5, and ketone 6 maintain binding with IC
50 50
respectively (Table 1). BRD4 degradation comparable to values of 2.3, 66.9, and 24.2 nM for BRD4, respectively.
amide3(D 80%),wasobservedfor4,5,and6(83%,76%, Notably, removal of the carbonyl moiety in alkane 5 does not
max
and85%at24h).Incomparison,theamineanalog7wasnot resultinasignificantlossinBRD4affinity(Table2).Looking
successful at degrading BRD4 with a DC of >11 μM. In attheRBAvalues,adecreaseisseenforester4,alkane5,and
50
general, the VHL-based PROTACs 19, 23−26, follow the ketone 6, (RBA: 2.4, 4.2, and 3.9, respectively, relative to 3).
sametrend inBRD4 degradation (seeFigure 6b), albeit DC This is possibly because these three analogs have higher
50
values are higher and D values lower. Ester 24 and ketone measured CHI LogD , correlating with an anticipated
max 7.4
26arethemostefficientdegradersofBRD4intheVHLseries, increase in permeability. All three of these analogs have the
withDC valuesof15.8and13.4nM(D valuesof89%and N−H group removed, so have one fewer HBD than amide 3.
50 max
79%,respectively)(Table1).VHL-derivedalkane25has∼20- TheSARtrendobservedforBRD4degradationhas4−6asthe
foldhigherDC anddiminishedD valuerelativetoCRBN- most potent degraders and the improvement in permeability
50 max
derived alkane 5, likely due to the reduced binding to BRD4 and BRD4 affinity could potentially explain the observed
andVHLproteins(seeTableS20inSupportingInformation). degradation. VHL degraders 19, 23−26 occupy less drug-like

To understand the observed BRD4 degradation results that space due to their higher molecular weight and larger number
arose from changing the linker, we measured target engage- of HBD but still show the same rank order in BRD4 target
mentoftheheterobifunctionaldegraderstoBRD4proteinand engagement and improved RBA values (see Supporting
the corresponding E3 ligase (Table 2). Binding affinity of the Information). However, the lower VHL affinity in live cell

PROTACs to BRD4 3−7 was assessed in a BRD4-BD1 nanoBRET for 19, 23−26 may explain the rightward shift in
biochemical probe displacement assay to bromodomain BD1. DC values (Table 1). High degradation efficacy of BRD4 is
50

VHL nanoluciferase-based bioluminescence resonance energy 83%.Amine7showsagreaterthan100-folddifferenceinIC
50
transfer (nanoBRET) assay dependent on the PROTAC between the live and permeabilized cells and this can be
synthesized. The cellular nanoBRET target engagement assay attributed to the basic amine in the linker hampering
was used as a surrogate to examine PROTAC cellular permeability into cells. Additionally, the BRD4 potency of
permeability.53 The assay was performed in both live and amine 7 is 453 nM compared to 16 nM for amide 3. Further
permeabilized (lytic) cells and intracellular availability was investigation of this significant shift in potency to the protein
determinedbycalculatingtherelativebindingaffinity(RBA).54 of interest was investigated computationally.

Journal of Medicinal Chemistry pubs.acs.org/jmc Article
differences in binding affinity of potent versus binders with 8b). Notably, amine 7 exhibits the weakest ternary complex
poor affinity, molecular dynamic (MD) simulations of BRD4- formation compared to other PROTACs, observed as the

BD1 in the presence of amide 3, ester 4, and amine 7 were lowest AUC (71.53) and a right-shifted dose response for
conducted in explicit solvent conditions. Sampled conforma- ternarycomplexformation(K =108nM),possiblyduetoits

Investigation of Ternary Complex Formation. To workhorse E3 ligase recruiters (CRBN and VHL). The ester,
explore how changing the PROTAC linkers influenced the ketone, and alkane transformations do not have the HBD
formation of a productive ternary complex, we evaluated moiety that is present in the amide analog, leading to higher

PROTAC induced ternary complex formation between logD values, increased cellular permeability, and lower RBA

CRBN/DDB1 and BRD4-BD1 in vitro, using an HTRF values in the E3 cell target engagement assay. The structural
assay (Figure 8a). When titrating the PROTAC compounds, changes also affect binding to the target protein of interest,
with removal of the carbonyl having the largest effect. These
combinedeffectsledtomorepotentdegraderswhentheamide
is exchanged for an ester, alkane, or ketone, but ineffective

BRD4 degraders were observed with an amine linker.

Experimental and computational studies indicate that amine
7showsweakertargetengagement,ternarycomplexformation,
and BRD4 degradation. New amine-acid coupling reactions
clearly impact the properties of PROTACs. These new
reactions enable the creation of matched pairs of degraders
with varied function. Taken together our results suggest a
systems chemistry approach can have a profound impact on
the biological activity of a molecule simply by modifying
reaction conditions when coupling the same two building
blocks.
■

Chemistry General. All reactions were conducted in oven- or

Figure8.ExperimentalPROTACs-driventernarycomplexformation flame-dried glasswareunder an atmosphereof nitrogen unlessstated
in vitro. (a) Ternary complex formation of CRBN/DDB1: otherwise.ReactionsweresetupinanMBraunLABmasterProGlove

PROTAC against the HTRF peak signal when treated with dBET6 of dry nitrogen gas. N-methylpyrrolidinone was purchased as
(98 nM) (see Supporting Information for structure of dBET6). anhydrous and degassed by sparging overnight with nitrogen. Other

Values reported are the mean ± SEM of a single experiment in solventswerepurchasedasanhydrousandusedasreceived.Reagents
duplicate for the CRBN-BRD4 ternary complex assay. (b) Assay werepurchasedfromSigma-Aldrich,AlfaAesar,OakwoodChemical,
metricsofternarycomplexformationconcentrationK andAUCfor Ambeed, or TCI Chemical. All chemicals were used as received.

TF
theternary complexformation by PROTACs 3−7. Glass1-dram (Fisherbrand parts No. 03-339-21B) or 2-dram vials
(Fisherbrand parts No. 03-339-21D or ChemGlass #CG-4912-02)
were used as reaction vessels, fitted with standard screwcaps (#03-
we observed “bell-shaped” dose response curves, typical of a
452-225or#03-452-300)orwithTeflon-coatedsiliconesepta(#CG-
4910-02 or CG-4910-02), and magnetic stir bars (Fisher Scientific
hook effect, at high concentrations of PROTACs due to
#14-513-93or#14-513-65;stirbars.com#SBM-0803-MICor#SBM-
increasingcompetitionfrombinarycomplexes.Theareaunder
1003-MIC).
thebell-shapedcurve(AUC) quantifiestheamountofternary 1HNMRspectrawererecordedonaVarianMR-500MHz,Varian
complex formed and correlates with its stability. The ternary MR-400 MHz, Bruker DPX, DRX, or AV spectrometers. Chemical
complex peak formation AC 50 values (K TF) for compounds shifts are reported in parts per million (ppm) and the spectra are
(3−7) correlate well with BRD4 degradation DC (Figure calibrated to the resonanceresulting fromincomplete deuteration of
50

Journal of Medicinal Chemistry pubs.acs.org/jmc Article
the solvent (CDCl: 7.26 ppm; DMSO-d:2.50 ppm, qn; MeOD- Upon completion of the reaction the reaction was worked up and
3 6
d:3.31 ppm, qn; Acetonitrile-d:1.94 ppm, qn). 13C NMR spectra purified asdescribed.
4 3
were recorded on the same spectrometers with complete proton General Procedure B Synthesis of Ester Products. An oven-
decoupling. Chemical shifts are reported in ppm with the solvent dried two-dram vial, equipped with a Teflon-coated stir bar, was
resonance as the internal standard (CDCl: 77.16 ppm, t; DMSO- charged with Katritzky salt (0.10 mmol, 1.0 equiv), carboxylic acid
3
d:39.52 ppm, sept; MeOD-d:49.00 ppm, sept, Acetonitrile-d 1.39 (0.10mmol,1.0equiv),potassiumtert-butoxide(11.2mg,0.10mmol,
6 4 3
ppm,m,128.39ppm, s.).Dataarereported usingthe abbreviations: 1.0equiv),andfinelygroundpotassiumiodide(32.0mg,0.20mmol,
app=apparent,s=singlet,d=doublet,t=triplet,q=quartet,p= 2.0equiv).Thevialwasthencapped,evacuated,andrefilledwithN
2
pentet, h = hextet, m = multiplet, comp = complex, br = broad. threetimes.1.00mLofdioxanewasaddedtothereactionvesselvia

Coupling constant(s) are reported in Hz. 19F NMR spectra were syringe,andthereactionheatedat110°Cfor22hatastirrateof500
recordedonthesamespectrometersasabove.13Cand19Fsignalsare rpm.Uponcompletion,thereactionwasfilteredthroughaCeliteplug
singletsunlessotherwisestated.1H−COSY,HSQCandHMBCwere
and washed with DCM. The filtrate was evaporated in vacuo and
usedwhere appropriateto facilitate structural determination. purified asdescribed.

High resolution mass spectrometry data (HRMS) were obtained GeneralProcedureB1OnePotSynthesisofEsterProducts.
on an Agilent 6230 TOF LC/MS equipped with ESI detector in Anoven-driedtwo-dramvial,equippedwithaTeflon-coatedstirbar,
positivemodeandonaMicromassAutoSpecUltimaMagneticSector was charged with amine hydrochloride salt (0.10 mmol, 1.0 equiv),
instrument with EI detector in positive mode. Reaction analysis was triphenylpyryliumtetrafluoroborate(39.6mg,0.10mmol,1.0equiv),
typically performed by thin-layer chromatography on silica gel or carboxylicacid(0.10mmol,1.0equiv),potassiumtert-butoxide(22.4
using a Waters I-class ACQUITY UPLC-MS (Waters Corporation, mg,0.20mmol,2.0equiv),andfinelygroundpotassiumiodide(32.0

Milford,MA,USA)equippedwithin-linephotodiodearraydetector mg,0.20mmol,2.0equiv).Thevialwasthencapped,evacuated,and
(PDA), evaporative light scattering detector (ELSD) and QDa mass refilled with N three times. 1.00 mL of dioxane was added to the
2
detector(BothESIpositiveandnegativeionizationmode).Typically reactionvesselviasyringe,andthereactionheatedat110°Cfor22h
0.1 μL sample injections were taken from acetonitrile solutions of
atastirrateof500rpm.Uponcompletion,thereactionwasfiltered
reaction mixtures orproducts (∼1 mg/mL). Apartial loop injection
through a Celite plug and washed with DCM. The filtrate was
modewasusedwiththeneedleplacementat2.0mmfrombottomof
evaporated invacuo and purifiedas described.
the wells and a 0.2 μL air gap at preaspiration and postaspiration. General Procedure C Synthesis of Alkane Products. In a

Teflon-coated stir bar, was charged with NiBr*glyme (12 mg, 0.04

Mobile Phase A: 0.1% formic acid in Optima LC/MS-grade water,
μLofNMP(vialA).Thiswasstirredwat500rpmfor30min.During

Flow rate: 0.8 mL/min. Column temperature: 45 °C. The PDA
stirbar,waschargedwithKatritzkysalt(0.10mmol,1.0equiv)(vial
sampling rate was 20 points/sec. The QDa detector monitored m/z

B).Anotheroven-driedtwo-dramvial,equippedwithaTeflon-coated
150−750withascantimeof0.06sandaconevoltageof30V.The
stirbar,waschargedwithacid(0.20mmol,2.0equiv),protonsponge

ELSDhadagainof750,datarateof10pps,timeconstant“normal”
(42.8mg,0.20mmol,2.0equiv),andTFFH(52.8mg,0.20mmol,2.0
0.2000s,agaspressureof40.0psi,withthenebulizerincoolingmode
equiv)(VialC).Thesevialsweretransferredtotheglovebox.VialC
at75%powerlevelandthedrifttubetemperaturesetto50°C.The
had 800 μL of NMP added and was stirred for 20 min followed by

PDAdetectorrangewasbetween210and400nmwitharesolutionof
addition into vial A. To vial C was added 400 μL of NMP and
1.2 nm. Two minute and 8 min methods were used. The method
manganese(22mg,0.40mmol,4.0equiv).Thisvialwasstirredat700
gradients are below: 2 min method, 0 min: 0.8 mL/min, 95% 0.1%
rpm for 2 min and transferred to vial A. Vial A was sealed with
formicacidinwater/5%0.1%formicacidinacetonitrile;1.5min:0.8
electricaltape,removedfromtheglovebox,andheatedat70°Cand
mL/min,0.1%0.1%formicacidinwater/99.9%0.1%formicacidin
800rpmfor14h.Uponcompletion,thereactionwasfilteredthrough
acetonitrile;1.91 min:0.8 mL/min,95% 0.1%formic acidinwater/
apadofCeliteusing30mLofethylacetate.Thefiltratewaswashed
5% 0.1% formic acid in acetonitrile. Eight min method, 0 min: 0.8
with 20 mL of saturated sodium sulfate. The organic layer was
mL/min, 95% 0.1% formic acid in water/5% 0.1% formic acid in
collected, dried with sodium sulfate and concentrated in vacuo.
acetonitrile; 7.5 min: 0.8 mL/min, 0.1% 0.1% formic acid in water/

Flash chromatography was performed on silica gel (230−400 nitrogenfilledglovebox,anoven-driedtwo-dramvial,equippedwitha

Teflon-coated stir bar, was charged with Nickel(II) bis-

Chromatography was performed on 25 μm TLC Silica gel 60 F254 (acetylacetonate) (12.5 mg, 0.04 mmol, 0.40 equiv), (Z)-N′-
glassplatespurchasedfromFisherScientific(partnumber:S07876). cyanopicolinimidamide (5.8 mg, 0.04 mmol, 0.40 equiv), and 800

Visualizationwasperformedusingultravioletlight(254and365nm)
μLofNMP(vialA).Thiswasstirredat500rpmfor30min.During
and/orpotassiumpermanganate(KMnO)stain.Reverse-phaseprep- thistime,anoven-driedtwo-dramvial,equippedwithaTeflon-coated
4

HPLC was performed on a Teledyne ISCO CombiFlash EZ Prep stirbar,waschargedwithKatritzkysalt(0.10mmol,1.0equiv)(vial
(RediSep Prep C18, 100 Å, 5 μm, 150 mm × 20 mm (part no. B).Anotheroven-driedtwo-dramvial,equippedwithaTeflon-coated
692203810))using0.1%formicacidinwaterand0.1%formicacidin stirbar,waschargedwithacid(0.20mmol,2.0equiv)(vialC).These
acetonitrileeluent. vialsweretransferredtotheglovebox.VialChad800μLofNMPand

General Procedure A Synthesis of Amide Products. A wasstirredat500rpmfor20minfollowedbyadditionintovialA.To
flamed-dried two-dram vial, equipped with a Teflon-coated stir bar, vialBwasadded400μLofNMPandmanganese(22mg,0.40mmol,
waschargedJQ1(40.0mg,0.1mmol,1equiv)andPyAOP(52.1mg, 4.0equiv,).Thisvialwasstirredat700rpmfor2minandtransferred
0.1 mmol, 1 equiv). To this vial was added dry DMF (0.5 mL) tovialA.Triethylaminehydrochloride(28mg,0.20mmol,2.0equiv)
followed by N-methyl imidazole (8.2 μL, 0.1 mmol, 1 equiv). The was added to the vial and it was capped, sealed with electrical tape,
resulting homogeneous solution was stirred at ambient temperature removedfromtheglovebox,andheatedat70°Cand800rpmfor14
for10min.Toanotherflamed-driedtwo-dramvialwasaddedamine h.Uponcompletion,thereactionwasfilteredthroughapadofCelite

HClsalt(0.1mmol,1equiv)andN-methylimidazole(12.3μL,0.15 using30mLofethylacetate.Thefiltratewaswashedwith20mLof
mmol,1.5 equiv)beforetheaddition ofDMF(0.5mL). Theamine saturatedsodiumsulfate.Theorganiclayerwascollected,driedwith
mixture was then transferred to the first vial. The combined sodium sulfate and concentrated in vacuo. Purification was achieved
homogeneous solution was stirred at ambient temperature for 14 h. asdescribed.

Journal of Medicinal Chemistry pubs.acs.org/jmc Article

Teflon-coated stir bar, was charged with Platinum(II) chloride (1.3 MHz, CDCl) δ 7.70 (m, 1H), 7.66 (dt, J = 8.1, 4.1 Hz, 1H), 7.47
3
mg,0.005mmol,0.05equiv)andBrettphos(5.3mg,0.01mmol,0.01 (dd,J=7.3,1.8Hz,1H),7.37(dd,J=8.6,2.6Hz,2H),7.26(dd,J=
equiv). 100 μL of 1:1 dioxane/DMSO was added and the solution 10.0,8.5Hz,2H),7.11(dd,J=8.4,6.0Hz,1H),4.86(dt,J=12.6,
stirredfor20minat30°Cand300rpm.Outsideoftheglovebox,an 4.6Hz,1H),4.61(dd,J=13.9,2.0Hz,1H),4.53(dd,J=13.9,11.3
additional oven-dried one-dram vial, equipped with a Teflon-coated Hz,1H),3.86(td,J=10.2,4.4Hz,1H),3.72−3.56(m,1H),3.17(q,
stirbar,waschargedwithamine(0.1mmol,1.0equiv)andcarboxylic J = 7.9, 7.0 Hz, 1H), 2.83−2.55 (m,4H), 2.61 (d, J = 6.7 Hz, 3H),
acid (0.15 mmol, 1.5 equiv). 900 μL of solvent was added. The 2.46(qt,J=12.4,4.5Hz,1H),2.34(d,J=3.8Hz,3H),2.05(dtd,J=
catalyst solution was removed from the glovebox, cooled to room 10.4,5.2,2.8Hz,1H),1.90−1.70(m,1H),1.70−1.50(m,5H),1.62
temperature,andphenylsilane(61μL,0.5mmol,5.0equiv)addedvia (s, 3H), 1.49−1.34 (m, 1H).13C NMR (126 MHz, CDCl 3) δ 171.8,
syringe. Note the solution will bubble vigorously and generate 171.7, 168.6, 168.4, 166.9, 166.7, 166.6, 166.2, 163.8, 156.3, 154.6,
hydrogen gas.The yellow solutionwas transferredvia syringe to the 154.6, 149.9, 137.0, 137.0, 136.8, 133.8, 132.2, 130.9, 130.7, 130.0,
amine/acidvialwhichwassubsequentlyheatedat70°Cfor16hand 129.9,128.9,128.8,119.7,119.6,118.5,117.5,68.3,68.2,57.5,57.3,
astirrateof500rpm.Uponcompletion,thereactionwasworkedup 49.6, 49.5, 39.2, 39.0, 31.6, 31.4, 29.6, 29.4, 27.3, 27.2, 27.0, 26.9,
andpurified asdescribed.. 23.0,14.6,14.6,13.3,12.0.HRMS(ESI)CalculatedC 37H 37ClN 7O 6S+
2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f]- [M + H]+:742.2209, Found742.2207.
[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(2-((2-(2,6-dioxopiper- N-(6-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f]-
idin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)acetamide [1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-5-oxohexyl)-2-((2-(2,6-diox-
(dBet1)(3).dBet1(compound3)waspreparedfrom1to2ona0.1 opiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (6). Com-
mmolscaleviageneralprocedureA.Uponcompletionofthereaction pound6waspreparedfrom1to10ona0.10mmolscalefollowing
itwasquenchedbytheadditionof20mLsaturatedaqueousNaSO generalprocedureD.Thecruderesiduewaspassedthroughaplugof
2 4
solution.Thephaseswerethenseparated,andtheaqueousphasewas silica gel to remove the triphenylpyridine. The plug was initially
extractedwithEtOAc(3×20mL).Thecombinedorganicfractions washedwith50mLofDCMfollowedby50mLof7%methanol in
were then washed with brine then dried over MgSO, filtered, and DCM.Themethanol/DCMfractionwasevaporated,reconstitutedin
4
concentrated in vacuo. The resulting residue was redissolved in acetonitrileandpurifiedviapreparativeHPLCtogivetogive21.3mg

Calculated C H ClNOS+[M +H]+: 785.2267, Found785.2268. 154.6, 149.9, 149.9, 137.0, 136.7, 133.6, 132.3, 132.2, 130.9, 130.8,
38 37 8 7 130.7,130.4,129.8,128.7,119.8,118.4,117.4,68.3,53.0,49.4,44.4,
4-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-
acetamido)butyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H- 44.3, 43.4, 43.4, 31.4, 28.7, 28.6, 22.7, 22.6, 21.0, 20.9, 14.4, 13.1,
thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate (4). 11.8.HRMS(ESI)CalculatedC 38H 37ClN 7O 7S+[M+H]+:770.2158,

N-(4-((2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-
general procedure B. Filtrate was reconstituted in acetonitrile and
f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)amino)butyl)-2-((2-
purifiedviapreparativeHPLCtogive42.5mg(54%)ofdesiredester
(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide
as an off white solid. Compound was also prepared via general
(7). Compound 7 was prepared from 1 to 2 on a 0.1 mmol scale
procedureB1inaonepotfashiontogive21.8mg(28%)ofdesired
relative to2 via general procedureE where solvent= DMSO.Upon
ester.UPLCRetentiontime2minmethod:1.06minR 93:7DCM/
f completion the reaction was quenched with 1 mL of methanol,

MeOH:1HNMR(600MHz,DMSO)δ10.90(s,1H),7.80(dd,J=
filteredthroughasyringefilter,andpurifiedviapreparativeHPLCto
8.5,7.2Hz,2H),7.51−7.41(m,6H),5.08(dd,J=12.5,5.5Hz,1H),
give 18.1 mg (23%) of desired amine as a white solid. UPLC
4.75(s,2H),4.50(dd,J=8.0,6.3Hz,1H),4.12(qt,J=10.9,6.4Hz, Retention time 2 min method: 0.82 min 1H NMR (500 MHz,
2H),3.48(dd,J=16.4,6.3Hz,1H),3.42(dd,J=16.4,8.0Hz,1H), DMSO)δ11.12(s,1H),8.55(s,2H),8.05(t,J=5.7Hz,1H),7.82
2.88 (ddd,J = 16.8,13.5, 5.7Hz, 1H), 2.65−2.54 (m,2H), 2.60 (s,
(dd,J=8.5,7.3Hz,1H),7.50(d,J=5.3Hz,5H),7.40(dd,J=8.7,
3H), 2.41 (s, 3H), 2.06 (tq, J = 7.9, 2.9 Hz, 1H), 1.67−1.59 (m, 3.4Hz,1H),5.15−5.07(m,1H),4.79(s,2H),4.32(dd,J=7.6,6.0
2H),1.64 (s, 3H), 1.52 (p, J = 6.9 Hz, 2H).13C NMR (151 MHz, Hz,1H),3.42−3.33(m,1H),3.31−3.23(m,1H),3.20(q,J=6.6Hz,

N-(5-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f]-
132.4, 130.6, 130.3, 130.0, 129.6, 128.5, 120.5, 117.5, 116.8, 116.1,
[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)pentyl)-2-((2-(2,6-dioxopi-
67.7, 53.9, 48.8, 46.6, 44.2, 37.8, 30.9, 28.1, 26.2, 23.1, 22.0, 14.1,
peridin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (5). Com-
12.6, 11.3. HRMS (ESI) Calculated C H ClNOS+ [M + H]+:
pound 5 was prepared from 1 to 10 on a 0.10 mmol scale via 38 40 8 7
771.2475, Found771.2469.
generalprocedureC.Thecruderesiduewaspassedthroughaplugof
(2S,4R)-N-(2-(3-(2-((2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-
silica gel to remove the triphenylpyridine. The plug was initially 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)ethyl)-
washedwith50mLofDCMfollowedby50mLof7%methanolin amino)ethoxy)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hy-

Journal of Medicinal Chemistry pubs.acs.org/jmc Article
to 13 on a 0.10 mmol scale relative to 13 via general procedure E 28.5,21.8,13.7.19FNMR(470MHz,cdcn)δ−76.86.HRMS(ESI)
3
wheresolvent=95:5dioxane/DMSO.Uponcompletion,thereaction Calculated C H ClNO+[M +H]+: 526.2467, Found526.2469.
29 37 3 4
mixturewasconcentratedinvacuoandredissolvedinacetonitrile(3 1-(5-(4-(6-((2-(1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-
mL, HPLC grade) then purified via preparative HPLC to 23 mg 1-yl)ethyl)amino)hexanoyl)piperazine-1-carbonyl)-2-
(22%) of desired amine. UPLC Retention time 2 min method: 0.93 methylphenyl)dihydropyrimidine-2,4(1H,3H)-dione (22). Com-
min1HNMR(400MHz,DMSO)δ8.27(s,1H),8.07(t,J=5.6Hz, pound 22 was prepared from 18 (etodolac) and 11 on a 0.100
1H),7.72(d,J=7.5Hz,1H),7.64−7.58(m,1H),7.50(dt,J=7.9, mmol scale relative to 11 via general via general procedure E on
where solvent = 3:7 DMSO/dioxane. When the reaction was
4.0Hz,1H),7.46(s,3H),7.35(d,J=7.6Hz,1H),7.00(d,J=8.3
complete after 5 h, it was cooled to room temperature and diluted

Hz,1H),4.75(d,J=10.6Hz,1H),4.57(d,J=18.0Hz,1H),4.46
with 30 mL of saturated sodium bicarbonate solution. This was
(q,J=9.7,8.4Hz,2H),4.36(d,J=4.5Hz,1H),4.31(dd,J=11.8,
extractedwithDCM(3×25mL).Theorganiclayerswerecombined,
5.8Hz,2H),4.13(ddt,J=20.2,13.7,6.6Hz,3H),3.79(dd,J=10.5,
washed with 30 mL of saturated sodium sulfate, dried over sodium
4.8 Hz, 1H), 3.68 (d, J = 10.3 Hz, 1H), 3.59 (t, J = 6.3 Hz, 1H),
sulfate, and concentrated. The residue was reconstituted in
3.56−3.44(m,2H),2.75(t,J=6.1Hz,1H),2.59(s,3H),2.56−2.42
acetonitrile and purified via prep HPLC to give 15.3 mg (23%) of
(m,9H),2.41−2.32(m,3H),2.24(s,1H),2.08−1.91(m,4H),1.64
the desired amine as a white solid. UPLC Retention time 2 min
(s,3H),0.97(d,J=6.5Hz,3H),0.77(d,J=6.7Hz,3H).13CNMR
method:0.85min1HNMR(499MHz,CDCl)δ10.75(s,1H),8.61
(151MHz,DMSO)δ171.6,168.1,167.5,163.2,155.9,155.4,151.5, 3
(s,1H),7.36(d,J=7.9Hz,1H),7.31(d,J=8.9Hz,3H),7.04(t,J=
149.7, 147.9, 142.2, 136.9, 135.2, 134.1, 132.3, 131.6, 131.4, 131.3,
7.4Hz,1H),6.99(d,J=7.1Hz,1H),4.09−4.02(m,1H),3.96(td,J
131.0, 130.5, 130.2, 129.9, 129.6, 128.5, 127.9, 127.8, 127.2, 127.0,
= 11.0, 3.8 Hz, 1H), 3.85−3.78 (m, 1H), 3.78−3.29 (m, 9H), 2.95
123.6,123.0,120.9,111.7,79.2,68.6,66.9,64.8,58.7,57.8,55.4,54.3,
(td,J=15.8,15.2,7.8Hz,2H),2.85(ddt,J=15.6,12.4,7.9Hz,6H),
48.0, 46.8, 45.3, 42.7, 38.1, 37.1, 29.0, 28.4, 18.9, 18.6, 16.0, 14.1,
2.76−2.66 (m, 2H), 2.53 (dd, J = 12.7, 6.5 Hz, 1H), 2.31 (s, 3H),
14.0, 12.7, 11.3. HRMS (ESI) Calculated C H ClNOS+ [M +
53 61 9 6 2 2.27−2.21(m,1H),2.17(s,1H),2.13(d,J=7.3Hz,1H),2.03(dt,J

H]+:1018.3869, Found1018.3862.
=14.9,7.5Hz,1H),1.90(dq,J=14.8,7.4Hz,1H),1.39(p,J=7.3
tert-Butyl 4-((2-((4S,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-

Hz,3H),1.32(d,J=7.6Hz,3H),0.97(t,J=7.4Hz,4H).13CNMR
phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-
(126MHz,CDCl)δ171.6,169.7,168.7,139.9,138.4,136.6,135.3,
1,3-dioxan-4-yl)ethyl)amino)piperidine-1-carboxylate (20). Com- 3
133.5, 131.4, 128.2, 127.1, 126.6, 126.5, 121.8, 120.7, 119.4, 115.7,
pound 20 was prepared from 17 and 15 on a 0.100 mmol scale
108.5,75.8,60.5,47.6,45.21,44.71,33.5,32.5,31.6,31.5,25.7,25.6,
relativeto15viageneralviageneralprocedureEonwheresolvent=
24.2, 23.7, 22.5, 18.1, 14.4, 8.0. HRMS (ESI) Calculated
3:7DMSO/dioxane.Whenthereactionwascompleteafter5h,itwas

C H NO+[M+ H]+: 685.4072,Found685.4067.
cooled to room temperature and diluted with 30 mL of saturated 39 53 6 5
(2S,4R)-N-(2-(3-(2-(2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-
sodiumbicarbonatesolution.ThiswasextractedwithDCM(3×25
thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)-
mL). The organic layers were combined, washed with 30 mL of ethoxy)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-
saturatedsodiumsulfate,driedoversodiumsulfate,andconcentrated. 3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxa-

HPLCtogive28.4 mg(37%)ofthe desiredamineasawhitesolid. scale following general procedure A. Upon completion the reaction

UPLCRetentiontime2minmethod:1.12min1HNMR(499MHz, wasquenchedbytheadditionof20mLsaturatedaqueousNaHCO
3

CDCl)δ7.16(dt,J=12.3,7.4Hz,9H),7.06(d,J=8.0Hz,2H), solution.Thephaseswerethenseparated,andtheaqueousphasewas
3
6.98(td,J=8.1,7.5,4.7Hz,3H),6.85(s,1H),4.08(m,4H),3.89− extractedwithEtOAc(3×20mL).Thecombinedorganicfractions
3.76(m,3H),3.65(dd,J=7.8,4.6Hz,1H),3.56(p,J=7.1Hz,1H), were then washed with brine then dried over MgSO 4, filtered, and
2.84(dq,J=6.8,4.1,2.9Hz,2H),2.81−2.66(m,3H),1.91(d,J= concentrated in vacuo. The resulting residue was redissolved in
12.7Hz,2H),1.68(q,J=6.8Hz,3H),1.52(d,J=7.1Hz,6H),1.44 MeCN (3 mL, HPLC grade) and purified via preparative HPLC to
(s,9H), 1.39 (d, J= 11.8 Hz, 2H), 1.33 (s,3H), 1.29 (s, 3H), 1.22 give48.5mg(47%)ofdesiredamideasawhitesolid.R f=0.37(10%
(dt,J=12.9,2.5Hz,1H),1.06(q,J=11.9Hz,1H).13CNMR(126 MeOH/DCM) UPLC Retention time 2 min method: 1.13 min 1H

C H FNO+[M + H]+: 767.4542,Found767.4539 =11.7,6.7Hz,2H),3.72(dh,J=21.3,6.1Hz,3H),3.58(d,J=5.7
46 60 4 5
tert-Butyl 4-((2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H- Hz, 2H),3.47(q, J=5.5 Hz,3H), 3.28(dd,J= 14.6,6.3Hz, 1H),
indol-3-yl)ethyl)amino)piperidine-1-carboxylate (21). Compound 2.56(s,4H),2.52−2.43(m,8H),2.39(s,4H),2.14(s,1H),1.65(s,
21 was prepared from 16 (indomethacin) and 15 via general 3H), 1.30−1.22 (m, 1H), 0.92(d,J = 6.5Hz, 3H), 0.85(d, J= 6.6
procedure E on a 0.20 mmol scale where solvent = 3:7 DMSO/

Hz,3H).13CNMR(126MHz,CDCl 3)δ170.7,170.2,163.9,156.9,
dioxane.Whenthereactionwascompleteafter3h,itwascooledto 142.2, 136.9, 136.7, 131.8, 131.7, 131.0, 130.6, 129.9, 129.7, 128.8,
128.0, 126.5, 123.9, 122.9, 121.8, 112.4, 69.9, 69.5, 67.7, 65.2, 58.8,
room temperature and diluted with 30 mL of saturated sodium
bicarbonate solution. This was extracted with DCM (3 × 25 mL). 58.7, 55.9, 47.4, 39.6, 39.2, 39.1, 36.4, 29.8, 29.5, 29.0, 19.2, 19.0,
16.3,14.5,13.2,11.8.HRMS(ESI)CalculatedC H ClNOS+[M

The organic layers were combined, washed with 30 mL of saturated 53 59 9 7 2
+ H]+: 1032.3662,Found1032.3660.
sodium sulfate, dried over sodium sulfate, and concentrated. The
2-(3-(2-(((2S,4R)-4-Hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-
resulting residue was purified by column chromatography using
2-yl)butanoyl)pyrrolidine-2-carboxamido)methyl)-5-(4-methylthia-

DCM/acetone/meOHtogive35.0mg(33%)ofthedesiredamineas
zol-5-yl)phenoxy)propoxy)ethyl 2-((S)-4-(4-chlorophenyl)-2,3,9-tri-
a yellow oil. The purified material had 20 μL of trifluoroacetic acid methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-
added to the NMR sample. UPLC Retention time 2 min method: acetate (24). Compound 24 was prepared from 1 to 13a on a 0.10
0.98 min 1H NMR (499 MHz, cd 3cn) δ 7.68−7.64 (m, 2H), 7.58− mmol scale via general procedure B. Filtrate was purified by flash
7.55(m,2H),7.10(d,J=2.5Hz,1H),6.99(d,J=9.0Hz,1H),6.71 chromatographyonsilicagelusingDCM/Acetone(50%)toMeOH/
(dd, J = 9.0, 2.5 Hz, 1H), 4.12 (d, J = 13.7 Hz, 2H), 3.84 (s, 3H), DCM(10%)aseluentto34.0mg(36%)ofdesiredesterasawhite
3.38−3.29(m,1H),3.28−3.19(m,2H),3.11−3.04(m,2H),2.73(d, solid.Compound24wasalsopreparedfrom1to13ona0.10mmol

Journal of Medicinal Chemistry pubs.acs.org/jmc Article

Hz,3H),6.93(dd,J=7.6,1.6Hz,1H),6.89(d,J=1.7Hz,1H),4.76 kitweresourcedatRevvity(64BRD4TPEH)andPromega(G7571),
(d,J=10.9Hz,1H), 4.73−4.66 (m,2H), 4.58−4.49 (m,3H), 4.46 respectively.TheHEK293cellswereharvestedat90%confluenceand
(dd,J=15.0,5.8Hz,1H),4.40−4.32(m,3H),4.26(ddd,J=11.8, then resuspended at the density of 1 × 106 cells per mL in 99%
6.0,3.7Hz,1H),4.14(t,J=6.0Hz,2H),3.78−3.68(m,5H),3.62− DMEMwith1%(v/v)FetalBovineSerum.Ina1536-wellassayplate
3.51(m,2H),2.61(s,3H),2.51(s,3H),2.46(m,1H),2.39(s,3H), (Corning,9145BC),5nLofserial-dilutedcompoundsweredispensed
2.18−2.09(m,3H),1.66(s,3H),0.93(d,J=6.5Hz,3H),0.85(d,J into4.5μLofcellspereachwell.Theplateswereincubatedat37°C
=6.5Hz,3H).13CNMR(126MHz,CDCl)δ170.7,170.2,163.9, with5%CO2for24h.FortheHTRFassay,1.5μLof1×HTFlysis
3
156.9, 142.2, 136.9, 136.7, 131.8, 131.7, 131.0, 130.6, 129.9, 129.7, bufferwasaddedtoeachwell.Afterincubationatroomtemperature
128.8,128.0,126.5,123.9,122.9,121.8,112.4,69.9,69.5,67.7,65.2, for 1 h, 1.5 μL of detection buffer (1:40 (v/v) dilution for both Eu
58.8, 58.7, 55.9, 47.4, 39.6, 39.2, 39.1, 36.4, 29.8, 29.5, 29.0, 19.2, cryptate and D2antibodies) was added into each well. The reaction
19.0, 16.3, 14.5, 13.2, 11.8. HRMS (ESI) Calculated wasfurtherincubatedforovernightatroomtemperaturebeforeplate

C H ClNOS+[M+ H]+: 1033.3502,Found1033.3502. reading by PHERAstar FSX using HTRF filter, channel A 337/665,
53 58 8 8 2
(2S,4R)-N-(2-(3-(4-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H- (60/400),channelB337/620(60/400).FortheCTGassay,4.5μL
thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)butoxy)- of 1×CTG solution was added to each well and the assay plate was
propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-meth-
incubated in dark at room temperature for 20 min to stabilize
yl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide
luminescent signal. The CTG signals were then measured by
(25).Compound25waspreparedfrom1to13aona0.10mmolscale

BRD4-BD1 Domain Biochemical Binding Assay. The HTRF
preparative HPLC to 21 mg (20%) of desired alkane product as a
biochemical assay is used to determine the binding affinity of the
whitesolid.UPLCRetentiontime8minmethod:4.19min1HNMR
testedBRD4bindingmoleculestotheBRD4bromodomain1(BD1).
(400MHz,cdcn)δ8.71(s,1H),7.70(d,J=7.5Hz,1H),7.61−7.40
3 Thisassaymeasurestheactivityoftestedcompoundsofthebinding
(m,6H),7.38−7.33(m,2H),7.31(d,J=8.0Hz,1H),7.25(t,J=6.1
betweenN-terminalGST-taggedBRD4-BD1domainandasynthetic

AnaSpec,64989)fromhumanhistoneH4.Ina384-wellwhitesmall-
6.1Hz,2H),3.97(dd,J=8.4,5.9Hz,1H),3.86(d,J=10.9Hz,1H),
volume plate (PerkinElmer, 6008289), 10 nL of serial-diluted
3.75(dd,J=10.9,4.3Hz,1H),3.64(t,J=6.1Hz,2H),3.58(td,J=
compounds were dispensed into 5uL binding domain diluent buffer
6.4,3.2Hz,2H),3.37(d,J=4.1Hz,1H),2.54(s,2H),2.45(s,3H),
(PerkinElmer,62DLBDDF).Subsequently,bothGST-taggedBRD4-
2.40(td,J=7.8,2.5Hz,1H),2.35(s,3H),2.15(s,3H),2.06(td,J=

BD1 protein and biotinylated BRD4 binding peptide were added to
12.6,5.5Hz,4H),1.86−1.73(m,1H),1.62(s,3H),0.92(d,J=6.5
the 10 mM and the mixture was incubated for 30 min at room

Streptavidin-D2 (CisBio, 610SADLB). After 3 h of incubation at
66.3, 60.0, 59.3, 57.7, 56.4, 48.0, 39.0, 38.4, 30.4, 29.7, 27.3, 21.1,
room temperature, the plates were measured in a PheraStar reader
19.4,19.0,16.5,14.6,13.1HRMS(ESI)CalculatedC H ClNOS+
[M+ H]+: 989.3604,Found989.3594. 52 58 8 6 2 FSX (BMG Labtech) using the homogeneous time-resolved
fluorescence (HTRF) optical module (excitation: 337 nm with 10
(2S,4R)-N-(2-(3-(4-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-
thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-3-oxobutoxy)- flashes; emission: 620 and 665 nm). The compound activity AC50
propoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-meth- values were calculated by fitting the data to the equation
yl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide “log(inhibitor) vs response − variable slope” using the GraphPad
(26).Compound26waspreparedfrom1to13aona0.95mmolscale Prismsoftware.
following a modified general procedure D where saturated sodium Cellular NanoBRET Target Engagement Assay. The cellular
sulfate was replaced with saturated sodium bicarbonate to remove NanoBRET target engagement assay for VHL and CRBN was
residual1.Thecruderesiduewaspassedthroughaplugofsilicagelto obtainedfromPromega(PromegaN2912,N2932).Theassayswere
remove the triphenylpyridine. The plug was initially washed with 50 conductedfollowingthemanufacturer’stechnicalmanualwithminor
mL of DCM followed by 50 mL of 10% methanol in DCM. The modifications. HEK293 cells were transiently transfected with the
methanol/DCMfractionwasevaporated,reconstitutedinacetonitrile NanoLuc-CRBNorNanoLuc-VHLfusionvectorusingtheFuGENE
andpurifiedviapreparativeHPLCtogive18.6mg(19%)ofdesired transfectionkit(PromegaE5911).After24hofincubationat37°C
ketone as a white solid. UPLC Retention time 2 min method: 4.01 with 5% CO, the cell lines were harvested and stored in liquid
2
min1HNMR(499MHz,CDCl)δ8.66(s,1H),7.77(d,J=7.2Hz, nitrogen. To analyze target engagement for CRBN and VHL E3
3
1H),7.50(td,J=7.3,1.1Hz,1H),7.42(d,J=8.0Hz,2H),7.41− ligases, these two cell lines were resuspended in Opti-Mem medium
7.25(m,8H),6.92(dd,J=7.6,1.6Hz,1H),6.84(d,J=1.6Hz,1H), (Gibco 11058-021) at a density of 5 × 105 cells per mL and
4.76 (d, J = 10.9 Hz, 1H), 4.72−4.63 (m, 2H), 4.56 (t, J = 7.5 Hz, dispensed into a 384-well plate (Corning 3574). For live cell
1H),4.55−4.49(m,1H),4.48 (dd,J= 5.9,4.0Hz,2H),4.40−4.34 NanoBRET measurement, these cell lines were treated with 0.5 μM
(m,2H),4.10(t,J=6.1Hz,2H),3.84(t,J=6.4Hz,1H),3.79−3.58 (CRBN) or 1 μM (VHL) tracer and serially diluted unlabeled
(m,5H),3.48(s,1H),2.99(dt,J=16.5,6.2Hz,1H),2.88(dt,J= PROTACcompoundsfor2hincubationat37°Cwith5%CO.In
2
16.5,6.5Hz,1H), 2.69−2.65(m,1H),2.57(s,3H), 2.54−2.45(m, thepermeabilizedcondition,beforedigitonintreatment(50μg/mL)
1H), 2.49 (s, 3H), 2.41 (td, J = 7.9, 7.1, 3.7 Hz, 2H), 2.38 (s, 3H), for 30 min, NanoLuc-CRBN or NanoLuc-VHL expressing cell lines
2.17−2.05(m,3H),1.72−1.65(m,1H),1.64(s,3H),0.91(d,J=6.5 were dosed with 0.15 μM (CRBN) or 0.25 μM (VHL) tracer and

Hz,3H),0.86(d,J=6.6Hz,3H).13CNMR(126MHz,CDCl)δ seriallydilutedunlabeledPROTACcompounds.Thereafter,bothlive
3
207.2, 170.8, 170.2, 169.4, 164.0, 156.9, 155.5, 150.3, 148.5, 142.3, andpermeabilizedcellsweretreatedwith1×Nano-Glosubstratefor
136.9, 136.8, 131.9, 131.8, 131.0, 130.9, 130.5, 129.9, 129.6, 128.8, 3 min (supplemented with 1× NanoLuc-extracellular inhibitor only
128.0, 126.5, 123.9, 123.0, 121.6, 112.1, 76.9, 70.2, 67.6, 65.8, 65.0, forthelivecellcondition).TheBRETsignalswerecollectedusinga
58.7, 56.0, 52.8, 47.5, 44.8, 44.1, 39.1, 36.3, 29.7, 28.9, 19.2, 19.1, PHERAstar FSXwiththeLUM2007H1module(610-LP, 450−480
16.2,14.5,13.2,11.8.HRMS(ESI)CalculatedC H ClNOS+[M nM).
53 58 8 7 2
+H]+:1017.3553,Found1017.3559. BRD4-PROTAC-CRBN Ternary Complex Formation HTRF

The HTRF and CellTiter-Glo (CTG) assays were conducted forthequantitativeevaluationoftheactivityoftestedcompoundsin
simultaneously using HEK293, cultured in 90% (v/v) DMEM bridging the interactionbetween the N-terminalGST-tagged BRD4-
(Gibco, 11995-065) with 10% (v/v) Fetal Bovine Serum (16000- BD1 domain (BPS, 31040) and the biotinylated CRBN/DDB1
044).TheHTRFtotalBRD4detectionkitandCellTiter-Glo(CTG) protein complex (prepared internally). In a 384-well white small-

Journal of Medicinal Chemistry pubs.acs.org/jmc Article
volume plate (PerkinElmer, 6008289), 20 nL of 2-fold serial-diluted TimCernak−DepartmentofMedicinalChemistry,University
compounds (Top concentration: 10 mM) were dispensed into each of Michigan, Ann Arbor, Michigan 48104, United States;
well in columns 1−22, with columns 23−24 containing 20 nL of orcid.org/0000-0001-5407-0643; Email: tcernak@
positive control (dBET6, final concentration: 98 nM) and DMSO,
med.umich.edu
respectively.The2×proteinmixturewaspreparedbycombiningthe
following components in the Binding Domain Diluent Buffer

Andrew McGrath − Department of Medicinal Chemistry,
and 200 nM CRBN/DDB1 protein complex. Subsequently, 5 μL of
the 2× protein mixture was added to each well, and the plate was UniversityofMichigan,AnnArbor,Michigan48104,United
incubated at room temperature for 1 h. To create the 2× detection States; orcid.org/0000-0001-9275-0017
solution, the anti-GST Eu3+ antibody (Revvity, 61HI2TLB) and Haiyan Huang − Department of Medicinal Chemistry,
streptavidin-d (Revvity, 610SADLB) were diluted with the Binding UniversityofMichigan,AnnArbor,Michigan48104,United
2

Domain Detection Buffer (Revvity, 62DB1FDG) to 2 and 100 nM, States
respectively.Followingthis,5μLofthedetectionsolutionwasadded Jean-Francois Brazeau − Therapeutics Discovery, Janssen
toeachwell,andtheplatewasincubatedatroomtemperaturefor3h

Zirong Zhang − Department of Medicinal Chemistry,
(excitation:337nmwith10flashes;emission:620and665nm).The

BRD4-PROTAC-CRBN ternary complex formation EC , ternary UniversityofMichigan,AnnArbor,Michigan48104,United
50
complex inhibition EC , peak B value and area under the curve States
50 max
(AUC) values were determined by fitting the data to the nonlinear Christopher O. Audu − Department of Medicinal Chemistry,
bell-shapedcurvemodel using GraphPad Prismsoftware. UniversityofMichigan,AnnArbor,Michigan48104,United

Research & Development, LLC, La Jolla, California 92121,
entry6BOY).55DDB1andCereblonproteinswereremovedfromthe

Schrödingersuite(version2023).56Compounds3(amide),4(ester), Development, LLC, Spring House, Pennsylvania 19477,
and 7 (amine) were prepared using the Ligprep module, and the United States
corresponding OPLS force-field parameters were calculated. Initial Zhicai Shi − Therapeutics Discovery, Janssen Research &
models were generated by aligning compounds 3, 4, and 7 to the Development, LLC, Spring House, Pennsylvania 19477,
bound dBET6 compound in the BRD4 crystal structure and United States
subsequently replacing the dBET6 ligand to create three models. Jennifer D. Venable − Therapeutics Discovery, Janssen

Research & Development, LLC, La Jolla, California 92121,
(Schrödinger suite).57 Models were solvated using SPC solvent

The finalized system underwent a 250 ns MD simulation, with Complete contact information is available at:
coordinates saved at intervals of 25 ps. Conformational analysis was https://pubs.acs.org/10.1021/acs.jmedchem.4c02047
then performed on the resulting trajectory to gain insights into the
dynamicpropertiesof the system.

DataAvailabilityStatementCodeusedtogeneratethetSNEas the manuscript.
wellasthepotencygraphics,SMILESstringsofallenumerated Funding
products, and an interactive version of the tSNE are available

Acid%20Couplings%20PROTACs. Notes
* sı Supporting Information The authors declare the following competing financial

The Supporting Information is available free of charge at interest(s): The authors declare the following competing
https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02047. financial inter-est(s): The Cernak Lab has received research
6BOY_model_amine (PDB) funding or in-kind donations from MilliporeSigma, Relay
6BOY_model_amide (PDB) Therapeutics, Janssen Therapeutics, SPT Labtech, AbbVie,
6BOY_model_ester (PDB) Entos, Inc. and Merck & Co., Inc. T.C. holds equity in

Corresponding Authors
purification (reverse phase HPLC) of select compounds and

Email: cgelin@its.jnj.com preparation of the manuscript.

Journal of Medicinal Chemistry pubs.acs.org/jmc Article
■

PreparationofThalidomide-ConjugateLinkers.Synlett2017,28(20),
(pentafluorophenyl)borane; BRET, bioluminescence reso- 2881−2885.
nance energy transfer; Bu 2O, dibutyl ether; CRBN, cereblon; (13)Bhela,I.P.;Ranza,A.;Balestrero,F.C.;Serafini,M.;Aprile,S.;

Permeability and Cellular Activity. J. Med. Chem. 2021, 64 (24),
formation AC50 values; ADME, absorption, distribution,
18082−18101.
metabolism and excretion; NaI, sodium iodide; NiBr •DME,
2 (15)Wurz,R.P.;Dellamaggiore,K.;Dou,H.;Javier,N.;Lo,M.-C.;
nickel(II) bromide·glyme; Ni(acac) , nickel(II) acetylaceto-
2 McCarter,J.D.;Mohl,D.;Sastri,C.;Lipford,J.R.;Cee,V.J.A“Click
nate; NEt •HCl, triethylammonium hydrochloride; POI,
3 Chemistry Platform” forthe Rapid Synthesis of Bispecific Molecules
protein of interest; PROTAC, proteolysis targeting chimera; forInducingProteinDegradation.J.Med.Chem.2018,61(2),453−

PSA, polar surface area; pyCamCN, (Z)-N-cyanopicolinimi- 461.
damide; RBA, relative binding affinity; RMSF, root-mean- (16) Brownsey, D. K.; Rowley, B. C.; Gorobets, E.; Gelfand, B. S.;
square fluctuation; tSNE, t-distributed stochastic neighbor Derksen, D. J. Rapid Synthesis of Pomalidomide-Conjugates for the
embedding; TEA, triethyl amine; TFFH, tetramethylfluor- DevelopmentofProteinDegraderLibraries.Chem.Sci.2021,12(12),
oformamidinium hexafluorophosphate; VHL, von Hippel- 4519−4525.
(17) Hayhow, T. G.; Borrows, R. E. A.; Dieǹ e, C. R.; Fairley, G.;

Explosion of Amine−Acid Reaction Space via Graph Editing.

Expanding the Medicinal Chemistry Synthetic Toolbox. Nat. Rev.

ExperimentationforInformation-RichChemicalSynthesis.Acc.Chem.

ChemicalSpace. Med.Chem. Commun.2019, 10(10),1755−1764. (30) Gruntz, U.; Katritzky, A. R.; Kenny, D. H.; Rezende, M. C.;
(11) Békés, M.; Langley, D. R.; Crews, C. M. PROTAC Targeted Sheikh,H.PyridinesasLeavingGroupsinSyntheticTransformations:

Journal of Medicinal Chemistry pubs.acs.org/jmc Article
(31) Ni,S.; Li,C.-X.; Mao,Y.;Han, J.; Wang, Y.;Yan, H.;Pan, Y. (50)Min,J.;Mayasundari,A.;Keramatnia,F.;Jonchere,B.;Yang,S.

Ni-Catalyzed Deaminative Cross-Electrophile Coupling of Katritzky W.;Jarusiewicz,J.;Actis,M.;Das,S.;Young,B.;Slavish,J.;Yang,L.;

ReductiveCross-ElectrophileCouplingsofAlkylpyridiniumSaltsand

DecarbonylativeCross-ElectrophileCoupling.J.Am.Chem.Soc.2023.

